Biotechnology Companies Making Major Announcements

LAS VEGAS, May 3, 2018 /PRNewswire/ --

FN Media Group Presents Microcapspeculators.com News Commentary 

The Nasdaq Biotechnology Index has is approximately 25% off of its all time high from back in July of 2015. With all of the incredible breakthroughs in biotechnology over the last few years, it is a very exciting time for those involved in biotech companies.  

On the heels of CVS Health's (CVS) big announcement that it plans to focus on kidney care and dialysis to improve patient outcomes and reduce costs, some other biotechnology companies that have made major announcements recently include: Endonovo Therapeutics, Inc. (OTC:ENDV), Heat Biologics, Inc. (NASDAQ:HTBX), Neovasc, Inc. (NASDAQ:NVCN), PTC Therapeutics, Inc. (NASDAQ:PTCT) and Akers Biosciences, Inc. (NASDAQ:AKER)

Endonovo Therapeutics, Inc. (QTCQB: ENDV)

Market Cap: $10.5M, current share price: $0.031 

ENDV, a commercial stage developer of wearable non-invasive Electroceutical™ therapies targeting post-operative pain and edema, chronic wounds, cardiovascular disease, renal disease and central nervous system disorders, recently highlighted positive results from an early feasibility study of its Electroceutical™ Therapy in reducing Proteinuria in 4 patients with chronic kidney disease (CKD). The Company is now planning to conduct a larger clinical trial in CKD.

The Company's Electroceutical™ therapy, SofPulse™, is an easy-to-place, non-invasive device that delivers targeted MicroCurrent Therapy (tMCT) to enhance post-surgical recovery. The Company's non-invasive Electroceutical™ therapy using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. ENDV recently stated that it is pursuing several sales and distribution channels in its 10-k annual report. The Company's strategy for commercialization centers on establishing SofPulse™ as standard care for post-surgical healing for the more than 850,000 cosmetic procedures performed each year in the US. Additionally, ENDV is establishing sales and distribution channels to target the Veteran's Affairs medical facilities and the more than 15,000 skilled nursing facilities in the United States.